...
首页> 外文期刊>MIMS Doctor. >Evidence for intensive platelet inhibition in ACS
【24h】

Evidence for intensive platelet inhibition in ACS

机译:证据在ACS密集的血小板抑制作用

获取原文
获取原文并翻译 | 示例
           

摘要

Dual antiplatelet therapy (DAPT) with aspirin and a thienopyridine is generally regarded as a cornerstone of treatment in the management of acute coronary syndromes (ACS) due to its efficacy in reducing the rate of ischaemic events. At a symposium held during the European Society of Cardiology (ESC) Congress 2019 and the World Congress of Cardiology (WCC) 2019 in Paris, France, experts reviewed the evidence behind intensive platelet inhibition in the treatment of ACS, with particular emphasis on the use of ticagrelor.
机译:双重抗血小板治疗(榫眼)和阿司匹林thienopyridine通常被认为是一个治疗管理的基石急性冠脉综合征(ACS)由于其在减少缺血性的功效事件。心脏病学协会(ESC)国会2019年世界心脏病学大会(WCC) 2019年在巴黎,法国,专家们回顾了证据密集的血小板抑制治疗ACS,特别强调使用

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号